Redpin Therapeutics

Kriya Therapeutics, Inc., a fully integrated gene therapy company advancing a broad portfolio of innovative therapeutics, today announced the acquisition of Redpin Therapeutics, Inc., a privately held biotechnology company developing regulatable gene therapies for intractable diseases of the nervous system. The acquisition serves as the foundation for Kriya’s neurology therapeutic area portfolio, with two lead gene therapy programs focused on epilepsy and trigeminal neuralgia (TN). Redpin’s proprietary chemogenetics platform can selectively activate or silence disease-causing neurons, while leaving normal functioning cells unaffected. Currently available treatments for neurological disorders typically rely on systemically administered drugs or surgical interventions to address local neuron…

Global patent estate significantly strengthened for Redpin’s innovative ion channel-based chemogenetics platform Redpin Therapeutics, Inc. (‘Redpin’ or the ‘Company’), a pioneering chemogenetics company developing uniquely controllable gene therapies to address intractable diseases of the nervous system, today announced the grant of four new patents by the US Patent and Trademark Office covering the Company’s proprietary chemogenetics platform. These patents, the latest of which was issued yesterday, significantly strengthen Redpin’s existing intellectual property position and are exclusively licensed to Redpin by the Howard Hughes Medical Institute, a leading medical research foundation in the US. Redpin is pioneering a novel cell therapy...

4BIO Capital and Arkin Bio Ventures lead first close joined by Takeda Ventures and existing investors Redpin Therapeutics, Inc., a pioneering chemogenetics company developing uniquely controllable gene therapies to address intractable diseases of the nervous system, today announced it has secured $15.5 million in the initial closing of its Series A financing round. The round was led by 4BIO Capital, an international venture capital firm focused solely on the advanced therapies sector, and Arkin Bio Ventures, the investment arm of Arkin Holdings, which specializes in pharmaceutical and biotechnology innovations that have imminent breakthrough potential, and joined by new investor Takeda...

Engineered receptors and ultrapotent, FDA-approved agonists enable clinical applications of chemogenetics Novel ion channel-based platform allows targeted cell activation or silencing controlled by low doses of the anti-smoking drug varenicline Redpin leveraging platform to advance pipeline of targeted cell therapies for currently intractable diseases of the nervous system Redpin Therapeutics, Inc., a gene therapy company leveraging its proprietary chemogenetics platform to advance targeted cell therapies that address currently intractable diseases of the nervous system, today announced the publication of a new paper in the journal Science describing the company’s foundational science. The paper, appearing online today, documents the discovery and...

Company advancing novel platform technologies to enable non-invasive, targeted regulation of neuronal cell activity Aiming to address currently intractable neurologic and psychiatric diseases Redpin Therapeutics today announced the appointment of David Bleakman, PhD, as its Chief Scientific Officer (CSO). Founded in 2017, Redpin is advancing novel platform technologies that enable the non-invasive, targeted regulation of neuronal cell activity in the brain to address crucial unmet needs for patients with severe neurological disorders. Redpin’s co-founders include Jeffrey Friedman, MD, PhD (Rockefeller University/Howard Hughes Medical Institute); Scott Sternson, PhD (Howard Hughes Medical Institute, Janelia Research Campus); Michael Kaplitt, MD, PhD (Weill Cornell...